Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Biomarker discovery

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Biomarker discovery. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-000586-19 Sponsor Protocol Number: 307971 Start Date*: 2005-07-25
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC)
    Medical condition: Non small cell lung cancer (NSCLC) stage IIIB or stage IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021951-26 Sponsor Protocol Number: UoL000621/R&D3963 Start Date*: 2011-04-15
    Sponsor Name:University of Liverpool [...]
    1. University of Liverpool
    2. Royal Liverpool and Broadgreen University Hospitals Trust
    Full Title: VIP: A prospective, phase II, double blinded, multicentre, randomised clinical trial comparing combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in locally advanced or m...
    Medical condition: Locally advanced or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033600 Pancreatic adenocarcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006639-24 Sponsor Protocol Number: 2020/ABM/01/00080 Start Date*: 2022-10-19
    Sponsor Name:The Cardinal Stefan Wyszyński Institute of Cardiology
    Full Title: Multicenter Polish Study of the Use of Bromocriptine in Perinatal Cardiomyopathy. New BioMarkers in the Early Diagnosis of Peripartum CardioMyopathy. PolBrom-PPCM
    Medical condition: PeriPartum Cardiomiopathy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002206-20 Sponsor Protocol Number: MK-3475-052 Start Date*: 2014-12-22
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer
    Medical condition: advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DK (Completed) IT (Completed) IE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004653-14 Sponsor Protocol Number: UoL000097 Start Date*: 2015-04-17
    Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust
    Full Title: A Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with Gemcitabine in patient with metastatic pancreatic carcinoma. (ACELARATE)
    Medical condition: Metastatic pancreatic carcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-000976-27 Sponsor Protocol Number: ML2017-IO1 Start Date*: 2017-07-26
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Biomarker discovery study to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatment
    Medical condition: advanced urothelial cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001175-31 Sponsor Protocol Number: ALM201/0001 Start Date*: 2014-10-10
    Sponsor Name:Almac Discovery
    Full Title: A phase I open-label multicentre dose-escalation study of subcutaneous ALM201 in patients with advanced ovarian cancer and other solid tumours.
    Medical condition: Advanced ovarian cancer and other solid tumours
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000658-27 Sponsor Protocol Number: D5130C05262 Start Date*: 2006-12-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute C...
    Medical condition: non-ST and ST elevation acute coronary syndromes (ACS)
    Disease: Version SOC Term Classification Code Term Level
    9 10011085 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) PT (Completed) HU (Completed) DE (Completed) FR (Completed) SE (Completed) AT (Completed) NL (Completed) DK (Completed) SK (Completed) BE (Completed) CZ (Completed) GR (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-023355-29 Sponsor Protocol Number: PO1425 Start Date*: 2011-05-18
    Sponsor Name:Papworth Hospital NHS Foundation Trust
    Full Title: Tyrosine kinase Inhibitors in DysplAsia of Lung epithelium Study 1
    Medical condition: High grade dysplasia of the bronchoepithelium
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10057004 Bronchial dysplasia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001128-31 Sponsor Protocol Number: 13-23 Start Date*: 2014-09-23
    Sponsor Name:Cancer Trials Ireland
    Full Title: Phase II Single-arm Study evaluating Neo-adjuvant (pre-radical radiotherapy) Abiraterone acetate (plus prednisolone) and Gonadotropin-Releasing Hormone (GnRH) agonist in high risk localised prostat...
    Medical condition: High-risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003712-23 Sponsor Protocol Number: CLAF237A23156 Start Date*: 2012-03-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 5-year study to compare the durability of glycemic control of a combination regimen with vildagliptin & metformin versus standard-of-care monotherapy with metformin, initiated in treatment-naive...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) FI (Completed) LV (Completed) IT (Completed) HU (Completed) DE (Completed) EE (Completed) SK (Completed) BG (Completed) PL (Completed) NO (Completed) CZ (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-020475-23 Sponsor Protocol Number: B0041007 Start Date*: 2010-10-05
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2 RANDOMIZED, DOUBLE-BLINDED, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED TWO COHORT TWO-WAY CROSS-OVER, MULTI-CENTRE CLINICAL TRIAL TO EXAMINE THE PAIN RELIEF PRODUCED BY 2 WEEKS OF DAILY...
    Medical condition: Chronic pain in patients with Osteo-arthritis.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001167-12 Sponsor Protocol Number: IMMUNED Start Date*: 2015-05-21
    Sponsor Name:University of Essen
    Full Title: A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanom...
    Medical condition: Stage IV melanoma with no evidence of disease after surgery or radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001144-22 Sponsor Protocol Number: ML28337 Start Date*: 2012-07-03
    Sponsor Name:ROCHE SAS
    Full Title: A RANDOMIZED, OPEN-LABEL, PHASE II STUDY ASSESSING THE EFFICACY AND THE SAFETY OF BEVACIZUMAB IN NEOADJUVANT THERAPY IN PATIENTS WITH FIGO STAGE IIIC/IV OVARIAN, TUBAL OR PERITONEAL ADENOCARCINOMA,...
    Medical condition: Epithelial ovarian cancer Fallopian tube carcinoma Primary peritoneal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000021045 10052204 Ovarian carcinosarcoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003455-21 Sponsor Protocol Number: GS-US-367-1171 Start Date*: 2016-02-12
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Di...
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    18.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-002328-35 Sponsor Protocol Number: CANTABRICO Start Date*: 2020-11-11
    Sponsor Name:AstraZeneca Farmacéutica Spain, S.A
    Full Title: A Phase IIIB, Single Arm Study, of Durvalumab in Combination with Platinum-Etoposide for Untreated Patients with Extensive-Stage Small Cell Lung Cancer reflecting Real World Clinical Practice in Sp...
    Medical condition: Extensive-Stage Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-021020-94 Sponsor Protocol Number: ACT11575 Start Date*: 2011-03-10
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate (MTX) in patients wi...
    Medical condition: active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-005120-41 Sponsor Protocol Number: GS-US-174-0103 Start Date*: 2005-07-21
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B.
    Medical condition: Chronic Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    15.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-005119-27 Sponsor Protocol Number: GS-US-174-0102 Start Date*: 2005-07-21
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of Presumed Pre-core Mutant Chronic Hepatitis B
    Medical condition: Chronic Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001484-23 Sponsor Protocol Number: Triple-B Start Date*: 2013-05-24
    Sponsor Name:BOOG Study Center
    Full Title: Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-line treatment in advanced triple negative Breast cancer
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 15:51:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA